Cortico-hippocampal APP and NGF levels are dynamically altered by cholinergic muscarinic antagonist or M1 agonist treatment in normal mice.
about
Nicotinic and muscarinic agonists and acetylcholinesterase inhibitors stimulate a common pathway to enhance GluN2B-NMDAR responses.Pre- and post-synaptic cortical cholinergic deficits are proportional to amyloid plaque presence and density at preclinical stages of Alzheimer's diseaseNonvascular retinal imaging markers of preclinical Alzheimer's disease.Loss of muscarinic M1 receptor exacerbates Alzheimer's disease-like pathology and cognitive decline.
P2860
Cortico-hippocampal APP and NGF levels are dynamically altered by cholinergic muscarinic antagonist or M1 agonist treatment in normal mice.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Cortico-hippocampal APP and NG ...... nist treatment in normal mice.
@en
Cortico-hippocampal APP and NG ...... nist treatment in normal mice.
@nl
type
label
Cortico-hippocampal APP and NG ...... nist treatment in normal mice.
@en
Cortico-hippocampal APP and NG ...... nist treatment in normal mice.
@nl
prefLabel
Cortico-hippocampal APP and NG ...... nist treatment in normal mice.
@en
Cortico-hippocampal APP and NG ...... nist treatment in normal mice.
@nl
P2093
P2860
P1476
Cortico-hippocampal APP and NG ...... nist treatment in normal mice.
@en
P2093
Andrew W Ferree
Hyemyung Seo
Ole Isacson
P2860
P304
P356
10.1046/J.0953-816X.2001.01884.X
P407
P577
2002-02-01T00:00:00Z